Looking to the future: New agents for chronic hepatitis B

American Journal of Gastroenterology

Volumn 101, Issue 1 SUPPL. 1, 2006, Pages s19-s25

  Dienstag, Jules L ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA2A INTERFERON; ANTIVIRUS AGENT; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ANTIVIRAL ACTIVITY; CHEMICAL ANALYSIS; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; HEPATITIS B; HEPATITIS C; HISTOLOGY; HUMAN; MYALGIA; PRIORITY JOURNAL; REVIEW; RIGOR; SEROLOGY; VIRUS REPLICATION;

EID: 33644923505     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.00377.x     Document Type: Review

References (29)

1. Seifer M Hamatake RK Colonno RJ et al In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir Antimicrob Agents Chemother 1998 42 3200 8
2. Chang TT Hadziyannis S Cianciara J et al Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine Hepatology 2002 36 4 Suppl 300A
3. Chang TT Gish R de Man R et al Entecavir is superior to lamivudine for the treatment of HBeAg(+) chronic hepatitis B: Results of phase III study ETV-022 in nucleoside-naïve patients Hepatology 2004 40 4 Suppl 1 193A
4. Shouval D Lai CL Cheinquer H et al Entecavir demonstrates superior histologic and virologic efficacy over lamivudine in nucleoside-naive HBeAg(-) chronic hepatitis B: Results of phase III trial ETV-027 Hepatology 2004 40 4 Suppl 1 728A
5. Honkoop P de Man RA Niesters HG et al Quantitative hepatitis B virus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients: Evidence of continuing viral suppression with longer duration and higher dose of lamivudine J Viral Hepat 1998 5 5 307 12
6. Sherman M Yurdaydin C Sollano J et al Entecavir is superior to continued lamivudine for the treatment of lamivudine-refractory, HBeAg(+) chronic hepatitis B: Results of phase III study ETV-026 Hepatology 2004 40 4 Suppl 1 664A
7. Peters MG Hann HW Martin P et al Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B Gastroenterology 2004 126 91 101
8. Gish RG Chang TT Hadziyannis S et al Lamivudine-refractory hepatitis B patients can be safely switched directly to entecavir 1 mg daily therapy J Hepatol 2004 40 Suppl 1 127
9. Collono RJ Rose R Levine SM et al Emergence of entecavir-resistant hepatitis B virus after one year of therapy in phase II & III studies is only observed in lamivudine refractory patients Hepatology 2004 40 4 Suppl 1 661A
10. Lai CL Leung NWY Teo EK et al Results of a one-year international phase IIB comparative trial of telbivudine, lamivudine, and the combination, in patients with chronic hepatitis B Hepatology 2003 38 4 Suppl 1 262A
11. Han SH Leung NWY Teo EK et al Results of a one-year international phase IIb trial of LDT, and LDT plus lamivudine, in patients with chronic hepatitis B J Hepatol 2004 40 Suppl 1 16
12. van Bömmel Wünsche T Schürmann D et al A comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus (HBV) infection Hepatology 2003 38 4 Suppl 246A
13. Kuo A Dienstag JL Chung RT Tenofovir dipivoxil fumarate for the treatment of lamivudine-resistant hepatitis B Clin Gastroenterol Hepatol 2004 2 266 72
14. Schiffman ML Ng TM Krastev Z et al A double-blind, placebo-controlled trial of emtricitabine (FTC, Emtriva) administered once-daily for treatment of chronic hepatitis B virus (HBV) infection Hepatology 2004 40 4 Suppl 1 172A
15. Lau G Cooksley H Ribeiro RM et al Randomized, double-blind study comparing adefovir dipivoxil (ADV) plus emtricitabine (FTC) combination therapy versus ADV alone in HBeAg(+) chronic hepatitis B: Efficacy and mechanisms of treatment response Hepatology 2004 40 4 Suppl 1 272A
16. Marcellin P Chang TT Lim SG et al Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B N Engl J Med 2003 348 808 16
17. Sung JJY Lai JY Zeuzum S et al A randomized double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naïve patients with chronic hepatitis B (CHB): Week 52 analysis J Hepatol 2003 38 Suppl 4313
18. Janssen HLA van Zonneveld M Senturk H et al Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial Lancet 2005 365 123 9
19. Schalm SW Heathcote J Cianciara J et al Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomized trial Gut 2000 46 562 8
20. Perrillo RP Schiff ER Davis GL et al A randomized, controlled trial of interferon alpha-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B N Engl J Med 1990 323 295 301
21. Lau GKK Piratvistuh T Luo KX et al Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N Engl J Med 2005 352 2682 95
22. Wong DKH Cheung AM O'Rourke K et al Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis Ann Intern Med 1993 119 312 23
23. Marcellin P Lau GKK Bonino F et al Peginterferon alfa-2a alone, lamividine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 2004 351 1206 17
24. Zeuzem S Feinman SV Rasenack J et al Peginterferon alfa-2a in patients with chronic hepatitis C N Engl J Med 2000 343 23 1666 72
25. Fried MW Shiffman ML Reddy KR et al Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 2002 347 13 975 82
26. Hadziyannis SJ Sette H Jr. Morgan TR et al Peginterferon alfa-2a and ribavarin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose Ann Intern Med 2004 140 5 346 55
27. Manesis EK Hadziyannis SJ Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B Gastroenterology 2001 121 101 9
28. Fung SK Wong F Hussain M et al Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B J Viral Hepat 2004 11 5 432 8
29. Mommeja-Marin H Mondou E Blum MR et al Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: Analysis and review of the literature Hepatology 2003 37 1309 19